Lorlatinib, a third-generation ALK inhibitor with enhanced BBB penetration, has shown efficacy in several pediatric and adult malignancies, including in a child with ALK-fused infant-type hemispheric glioma (IHG) (82). This evidence concerns the gene ALK and central nervous system cancer.